IMNR – The Immune Response Corporation
StockGuru Profile IMNR
David Hochman Interview – Value Mission
This Stock Represents and Incredible Bargain and the Stakes are Huge
Current Price: $0.0197 and Target Price $0.059
There are several American Dreams but one of the greatest is: “Let’s do some good, have some fun, and make some money – and maybe, just maybe change the world for the better.”
That’s the opportunity that IMNR presents. This is a biotech company that is working on autoimmune diseases and infectious diseases. This includes HIV and autoimmune diseases including Multiple Sclerosis, Psoriasis, and Rheumatoid Arthritis.
IMNR product pipeline has two clinical stage therapeutics in Phase II development: NeuroVax(TM) for multiple sclerosis (MS), and IR103 for HIV/AIDS.
Today we bring you a cursory overview and in the coming days we will examine each revenue analysis in the Spelman Research Report.
Pricing:
We would direct you to the Spelman Report on IMNR. The Spelman Research Report on The Immune Response Corporation is available at: http://www.roiny.com/clients-irc-research.php?f=IMNR-Spelman-Research-Report.pdf
In essence it reveals a target price for IMNR that includes the full story:
Target Price IMNR: $.059 per share
Current Price IMNR: $0.0197
The Value Proposition Is Serious
Let’s examine IMNR comparable’s analysis. Companies that are targeting diseases such as Multiple Sclerosis and HIV which are in Phase Two Clinical Trials – trade at five to ten times the value of IMNR. And we will take a closer look at this tomorrow.
A Phase II double blind study will provide a clear look at potential benefit and role of Neurovax. And this study will be complete within eighteen months.
Phase I and II trials performed for both NeuroVax™ and IR103 have shown each drugs’ good safety profile and suggest their clinical efficiency. While further clinical research is required, this preliminary data suggests a relatively high probability of success.
Phase II trials results if successful, should attract significant public and private partnerships for Phase III trials. Discussions about Phase III trials partnerships are already underway.
Revenue Generation Potential is Enormous
The Revenue generation potential for Neurovax from the perspective of a licensing partnership with major pharmaceutical company that is already active in the MS space or wants to leverage that space in a big way is enormous.
Stay tuned as we examine valuation process of a company with two blockbuster drugs in the pipeline.
For further information contact:
ROI Group Associates
39 Broadway; NY, NY 10006
212.495.0744
MDodge@roiny.com
Source: Spelman Research Report and D. Hochman
IMNR — Immune Response Corp. (The)
5931 Darwin Court
Carlsbad, CA 92008
Website: http://www.imnr.com
Phone: 760-431-7080
Forward Looking Statement and Safe Harbor: Any information regarding The Immune Response Corporation (”IMNR”) in this communication is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO ITS OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. ROI Group Associates, Inc. (”ROI”) is the investor relations counsel for IMNR and accepts compensation from the IMNR for this effort, including a monthly cash retainer and restricted stock. Under the terms of its investor relations Service Agreement, ROI has agreed not to sell any of the IMNR restricted stock received as compensation under the Service Agreement during the entire term of its engagement as IMNR’s investor relations counsel pursuant to this Service Agreement. ROI shall be under no obligation to update readers about any restrictions on its trading activities regarding IMNR.
In addition to MS, IMNR has opened Investigational New Drug Applications (IND) with the U.S. Food and Drug Administration (FDA) for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis. IR103 is based on their patented whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of REMUNE® , our first-generation HIV product candidate. IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. IMNR is currently testing IR103 in two Phase II clinical studies as a first-line treatment for drug-naïve HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines. In early 2006 IMNR made a strategic decision to accelerate the development of IR103, rather than pursue a Phase III trial with REMUNE® . All of IMNR products are still in the development stage. IMNR has never had revenues from the sale of products. IMNR was founded in 1986.
Forward Looking Statement: This news release may contain forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. While these statements are meant to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. While management believes such representation to be true and accurate based on the information available to the company, actual results may differ materially from those described. The company’s operations and business prospects are always subject to risks and uncertainties. Important facts that may cause actual results to differ are set forth in IMNR’s periodic filings with the U.S. Securities and Exchange Commission.
Disclosure: Pentony Enterprises LLC was compensated $50,000 from ROI Group Associates Inc. for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
Disclosure: StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco , Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com . Email: Publisher@stockguru.com.
